Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial)

資料種別:
論文(リポジトリ)
責任表示:
Hama, Taketsugu ; Nakanishi, Koichi ; Ishikura, Kenji ; Ito, Shuichi ; Nakamura, Hidefumi ; Sako, Mayumi ; Saito-Oba, Mari ; Nozu, Kandai ; Shima, Yuko ; Iijima, Kazumoto ; Yoshikawa, Norishige
言語:
英語
出版情報:
Springer Nature, 2018-09-10
著者名:
Hama, Taketsugu
Nakanishi, Koichi
Ishikura, Kenji
Ito, Shuichi
Nakamura, Hidefumi
Sako, Mayumi
Saito-Oba, Mari
Nozu, Kandai
Shima, Yuko
Iijima, Kazumoto
Yoshikawa, Norishige
続きを見る
掲載情報:
BMC Nephrology
ISSN:
1471-2369  CiNii Articles  Webcat Plus  JAIRO
巻:
19
バージョン:
publisher
概要:
Background: Eighty percent of children with steroid-sensitive nephrotic syndrome (SSNS) relapse within 2 years and 40-50% patients show frequently-relapsing nephrotic syndrome (FRNS). Patients showing a relapse within 6 months after initial remission are at high risk of FRNS. Since frequent prednisolone treatment for FRNS induces severe prednisolone side effects, development of a treatment to prevent patients from shifting to FRNS is desirable. Mizoribine is an immunosuppressive drug with fewer side effects than prednisolone. Recent studies reported the efficacy of high-dose mizoribine in children with FRNS. Methods/design: We conduct a multicenter, open, randomized controlled trial to investigate the efficacy and safety of standard prednisolone plus high-dose mizoribine therapy in children with SSNS showing a relapse within 6 months after an initial remission. Patients are allocated to either standard prednisolone alone treatment group, or standard prednisolone plus high-dose mizoribine group. For the former group, mizoribine is administered at a dose of 10 mg/kg/day once daily and continued for 2 years. The primary endpoint is the duration to frequent relapse. Discussion: The results provide important data on use of high-dose mizoribine to prevent SSNS patients from shifting to FRNS. Since blood concentrations of mizoribine have not been investigated in detail until now, there is a possibility that mizoribine is underestimated in favor of other immunosuppressive drugs. In future, high-dose mizoribine therapy may lead to prevention of relapse in children at high risk of FRNS, and to decreased total dose of prednisolone. 続きを見る
URL:
http://hdl.handle.net/20.500.12000/45852
eリソース
Loading

類似資料:

1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
11
 
12
 

Horinouchi, Tomoko, Sako, Mayumi, Nakanishi, Koichi, Ishikura, Kenji, Ito, Shuichi, Nakamura, Hidefumi, Oba, Saito Mari, …

Springer Nature

Horinouchi, Tomoko, Yamamura, Tomohiko, Minamikawa, Shogo, Nagano, China, Sakakibara, Nana, Nakanishi, Koichi, Shima, …

Wiley Open Access

Nagano, China, Sako, Mayumi, Kamei, Koichi, Ishikura, Kenji, Nakamura, Hidefumi, Nakanishi, Koichi, Omori, Takashi, …

Springer Nature

Yamamura, Tomohiko, Nozu, Kandai, Miyoshi, Yuya, Nakanishi, Keita, Fujimura, Junya, Horinouchi, Tomoko, Minamikawa, …

Springer Nature

Nagano, China, Yamamura, Tomohiko, Horinouchi, Tomoko, Aoto, Yuya, Ishiko, Shinya, Sakakibara, Nana, Shima, Yuko, …

Springer Nature

Imafuku, Aya, Nozu, Kandai, Sawa, Naoki, Nakanishi, Koichi, Ubara, Yoshifumi

Springer

Fujimura, Junya, Nozu, Kandai, Yamamura, Tomohiko, Minamikawa, Shogo, Nakanishi, Keita, Horinouchi, Tomoko, Nagano, …

Elsevier

Trautmann, Agnes, Vivarelli, Marina, Samuel, Susan, Gipson, Debbie, Sinha, Aditi, Schaefer, Franz, Hui, Ng Kar, Boyer, …

Springer

Yamamura, Tomohiko, Nozu, Kandai, Minamikawa, Shogo, Horinouchi, Tomoko, Sakakibara, Nana, Nagano, China, Aoto, Yuya, …

Wiley

Nakanishi, Shotaro, Miyazato, Minoru, Miyagi, Ryota, Saito, Seiichi

Elsevier

Horinouchi, Tomoko, Nozu, Kandai, Yamamura, Tomohiko, Minamikawa, Shogo, Nagano, China, Sakakibara, Nana, Nakanishi, …

Springer Nature

Nakanishi, Shotaro, Nishida, Sho, Miyazato, Minoru, Goya, Masato, Saito, Seiichi

Elsevier